OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The procedures have been performed by Dr. Kaushal Pandey at P.D. Hinduja Hospital in Mumbai, India
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
As an initial remote monitoring diagnostic approach, Philips BioTel Heart MCOT detected 4.6 times more patients with atrial fibrillation compared to implantable loop recorder alone
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
Dabigatran Etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE)
Subscribe To Our Newsletter & Stay Updated
